The Binaytara Foundation (BTF) was established in 2007 by Dr. Binay Shah and wife Tara Shah with the goal of promoting health and education in underprivileged societies. The BTF is a Washington State nonprofit organization exempt from taxation pursuant to Section 501(c)(3) of the Internal Revenue Code. BTF has founded multiple programs in underdeveloped and developing countries to improve access to healthcare. Recent accomplishments include building a 25-bed cancer hospital in Nepal in 2018 and breaking ground on their new 200-bed facility in 2022.
Current projects
Upcoming Conferences of 2023:
2023 Wisconsin Multiple Myeloma & Lymphoma Summit: August 26, 2023 This CME-accredited activity features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of multiple myeloma, lymphoma, and Waldenström Macroglobulinemia. This activity aims to improve learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances in newly diagnosed and relapsed multiple myeloma and lymphomas with a focus on emerging immunotherapies, including but not limited to CAR-T therapy and T-cell redirecting bispecific antibodies. Expert faculty will aim to place the role of different therapeutic agents in clinical contexts and discuss how to utilize these therapeutic options to effectively contribute to patient care.
2023 ANNUAL SUMMIT ON HEMATOLOGIC CANCERS: INCORPORATION OF NOVEL THERAPIES IN CLINICAL PRACTICE: September 15 - 17, 2023 This CME-accredited activity features leading experts in hematologic malignancies who will provide a comprehensive overview of current and emerging strategies for the management of acute myeloid leukemia, acute lymphoblastic leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, myeloproliferative neoplasms, multiple myeloma, and lymphoma. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies. The program features in-depth discussion and analysis of the latest scientific findings and practice-changing advances along with case-based discussion in the field of hematologic malignancies. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care.
2023 CANCER IMMUNOTHERAPY SUMMIT: EVERYTHING, EVERYWHERE, ALL AT ONCE OF CANCER IMMUNOTHERAPY: September 22 & 23, 2023 This CME-accredited conference features leading experts in the field who will provide a comprehensive overview of current and emerging strategies to integrate immunotherapy in the management of cancers. These experts will offer their insights on mechanisms of immunotherapy toxicity, host factors regulating efficacy and resistance, and neoadjuvant immunotherapy, all in the pursuit of improving patient outcomes. This activity aims to enhance learners' knowledge and competence to apply practice-changing clinical data and expert recommendations to incorporate immunotherapy and optimize clinical outcomes for cancer patients. The oncology conference will use a mix of didactic lectures and case-based panel discussions to highlight areas of debate in the field of immuno-oncology. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to contribute effectively to patient care.
2023 ANNUAL SYMPOSIUM FOR EVOLVING THERAPIES AND DRUG DEVELOPMENT IN ONCOLOGY: TARGETED THERAPY, IMMUNOTHERAPY AND BEYOND: September 29 & 30, 2023 A two-day conference aimed at improving the knowledge and competence of academic and community oncology providers on the biomarker-guided treatment of cancer, and design and conduct of clinical trials in the era of novel therapies. The activity will use a mix of didactic lectures and panel discussions to highlight various aspects of precision oncology, including current challenges and opportunities in designing clinical trials in the era of novel therapies.